Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer

Anti-Cancer Drugs

Volumn 9, Issue 6, 1998, Pages 577-579

  Benjapibal, Mongkol ^a   Kudelka, Andrzej P ^b   Vasuratna, Apichai ^c   Edwards, Creighton L ^b   Verschraegen, Claire F ^b   Valero, Vicente ^b   Vadhan Raj, Saroj ^b   Kavanagh, John J ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b UNIVERSITY OF TEXAS   (United States)

^c KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Cisplatin; Cyclophosphamide; Docetaxel; Ovarian cancer; Paclitaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; PLATINUM;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CASE REPORT; DOSE RESPONSE; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROTUBULE ASSEMBLY; OVARY CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031849579     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199807000-00009     Document Type: Article

References (26)

1. Thigpen JT, Vance RB, Lambuth BW. Ovarian carcinoma: the role of chemotherapy. Semin Oncol 1988; 15: 16-23.
2. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654-66.
3. Sarosy G, Kohn E, Stone DA, et al. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 1992; 10: 1165-70.
4. Kavanagh J, Kudelka A, Edwards C, et al. A randomized crossover trial of parenteral hydroxyurea vs high dose taxol in cisplatin/carboplatin resistant epithelial ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 259.
5. Mangatal L, Adeline MT, Guenard D, et al. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 1989; 45: 4177-90.
6. Denis JN, Greene AE, Guenard D, et al. A highly efficient practical approach to natural taxol. J Am Chem Soc 1988; 110: 5917-9.
7. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51: 4845-52.
8. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991; 83: 288-91.
9. Hanauske AR, Degen D, Hilsenbeck SG, et al. Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anti-Cancer Drugs 1992; 3: 121-4.
10. Valero V. Treatment of patients resistant to paclitaxel therapy. Anti-Cancer Drugs 1996; 7 (suppl): 17-9.
11. Moore DH, Fowler WC Jr, Jones CP, et al. Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer. Am J Obstet Gynecol 1991; 165: 573-6.
12. Sutton GP, Blessing JA, Homesley HD, et al. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 1989; 7: 1672-6.
13. Schink JC, Harris LS, Grosen EA, et al. Altretamine (hexalen) an effective salvage chemotherapy after paclitaxel (taxol) in women with recurrent platinum resistant ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275.
14. Bissery MC, Vrignaud P, Bayssas M, et al. Taxotere synergistic combination with cyclophosphamide, etopo side, and 5-fluorouracil in mouse tumor models (abstract). Proc Am Ass Cancer Res 1993; 34: 1782.
15. Bissery MC, Vrignaud P, Lavelle F. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 1995; 22 (suppl 13): 3-16.
16. Vadhan-Raj S, Verschraegen C, McGarry L, et al. Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin-induced thrombocytopenia in patients with gynecologic malignancy. J Am Soc Hematol 1997; 90 (suppl 1): 580a.
17. Vadhan-Raj S, Verschraegen C, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic malignancy. Submitted.
18. Valero V. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors: preliminary results of a phase I study. Oncology 1997; 11 (suppl 8): 38-40.
19. Gueritte-Voegelein F, Guenard D, Levelle F, et al. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-8.
20. Kelland LR, Abel G. Comparative in vitro cytotoxicity of taxol and taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 1992; 30: 444-50.
21. Piccart MJ, Gore M, ten Bokkel Huinink WW, et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J Natl Cancer Inst 1995; 87: 676-81.
22. Aapro MS, Pujade-Lauraine E, Lhomme C, et al. Phase II study of taxotere in ovarian cancer. Proc Am Soc Clin Oncol 1993; 12: 256.
23. Kavanagh J, Kudelka A, Gonzalez de Leon C, et al. Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 1996; 2: 837-42.
24. Francis P, Schneider J, Hann L, et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 1994; 12: 2301-8.
25. Verschraegen C, Kudelka A, Steger M, et al. Randomized phase II study of two dose levels of docetaxel in patients with advanced epithelial ovarian cancer who have failed paclitaxel chemotherapy. Proc Am Soc Clin Oncol 1997; 16: 381a.
26. Young RC, Perez CA, Hoskins WJ. Cancer of the ovary. In: Devita VT, Hellman S, Rosenberg SA, eds. Principles and practice of oncology. Philadelphia: Lippincott 1993: 349-95.